Close this search box.

Organigram Signs 2nd UK Supply Deal With Avida Medical

Canadian cannabis giant Organigram has announced a new three-year supply deal in the UK as it continues to focus efforts on international expansion.

Earlier this week (May 28), Organigram announced that it had signed a new deal with UK medical cannabis operator Avida Medical, marking its second deal in the country after signing a similar deal with 4C Labs in August 2023.

Avida will now have strain exclusivity for three of Organigram’s products in the UK, with the latter expected to supply 1700kg of flower over the three-year period, including 500kg in the first year.

“We are confident that this strategic move will not only strengthen our international presence but also reinforces our objective of advancing global access to medical cannabis,” Organigram’s CCO Tim Emberg said.

This marks the latest push into international markets from the Canadian operator, which has been vocal about the issues facing cannabis companies in its home market for some time.

Last July, Business of Cannabis reported that Organigram cited ‘THC inflation’ as a ‘meaningful contributing factor’ to its fall in revenues and profits, impacting ‘flower sales and margins’.

As such, like many of its Canadian counterparts, Organigram is turning to the international medical cannabis market, where it can achieve a better margin on sales.

To date, Organigram has signed seven supply deals in the UK, Germany, Australia and Israel.

“The UK is home to one of the largest patient populations using medicinal cannabis in Europe, and this is set to grow exponentially over the next four years,” Avida’s CEO, Paul Parkinson, said.

“As the market matures, it is those producers and manufacturers that have focused on ensuring the highest quality of their products and processes, that will determine the companies that succeed.”


Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?